What is MNPR stock price today?

MNPR (Monopar Therapeutics) stock is trading at $70.00 as of the latest market data. Stock prices update in real-time during market hours (9:30 AM - 4:00 PM ET).

Is MNPR stock going up or down today?

MNPR stock price movements are influenced by market conditions, news, earnings reports, and investor sentiment. Check our live dashboard for real-time price changes and technical indicators.

Should I buy MNPR stock now?

The decision to buy MNPR depends on your investment strategy, risk tolerance, and financial goals. Our AI analysis evaluates fundamentals, valuation metrics, growth prospects, and market conditions to help inform your decision.

Is MNPR a buy, hold, or sell right now?

Our AI-powered analysis provides buy/hold/sell recommendations for MNPR based on multiple factors including valuation, growth metrics, technical indicators, and analyst consensus. Visit our dashboard for the latest recommendation.

Is MNPR stock overvalued or undervalued?

Use our DCF valuation calculator to determine if MNPR is overvalued or undervalued based on fundamental analysis and future cash flow projections.

What is MNPR's P/E ratio?

P/E ratio data for MNPR will be available after the company reports earnings. Visit our dashboard for the latest financial metrics.

What is MNPR's market cap?

MNPR (Monopar Therapeutics) has a market capitalization of $0.47 billion, making it a small-cap stock.

What is MNPR's price to book ratio?

MNPR trades at a price-to-book (P/B) ratio of 3.30, which compares the stock price to the company's book value per share. A P/B below 1.0 may indicate undervaluation, while above 3.0 may suggest premium pricing.

Does MNPR pay dividends?

MNPR does not currently pay dividends. Many growth companies reinvest profits into the business rather than paying dividends.

What is MNPR's dividend yield?

MNPR does not currently pay dividends or dividend data is not available. Check our dashboard for the latest information.

Is MNPR stock a good long-term investment?

MNPR's long-term investment potential depends on sustainable competitive advantages, revenue growth, profitability, management quality, and industry dynamics. Our AI analysis evaluates these factors to assess long-term prospects.

What is MNPR's revenue growth rate?

Revenue growth data for MNPR is available on our dashboard with detailed financial statement analysis.

Profitability metrics for MNPR are available on our dashboard with complete income statement analysis.

What are the risks of investing in MNPR?

Key risks for MNPR include market volatility, competitive pressures, regulatory changes, economic conditions, execution risks, and company-specific factors. Our AI analysis identifies material risks and their potential impact on valuation.

How does MNPR compare to its competitors?

Compare MNPR to industry peers on our dashboard using metrics like P/E ratio, revenue growth, profit margins, market share, and valuation multiples. Competitive analysis helps contextualize MNPR's performance and positioning.

What is MNPR's stock price target for 2026?

Our AI model provides price targets for MNPR based on fundamental analysis: Bull case $91.00 (+30%), Base case $80.50 (+15%), Bear case $63.00 (-10%). Visit our prediction page for detailed forecasts.

What do analysts say about MNPR?

Wall Street analysts provide ratings (buy/hold/sell) and price targets for MNPR. Our dashboard aggregates analyst consensus, target prices, and recent upgrades/downgrades to help you understand professional sentiment.

When is MNPR's next earnings report?

MNPR reports earnings quarterly. Check our dashboard for the upcoming earnings date, analyst estimates for revenue and EPS, and historical earnings performance. Earnings reports often drive significant stock price movements.

MNPR - Monopar Therapeutics

NYSE * Health Care * Biotechnology

$70.00

+$0.93 (+1.35%)

About Monopar Therapeutics

Monopar Therapeutics Inc., a clinical-stage biopharmaceutical company, engages in developing therapeutics for the treatment of cancer in the United States. The company develops ALXN1840, a late-stage, investigational once-daily and oral medicine; MNPR-101, a proprietary humanized monoclonal antibody that is conjugated with different radioisotopes for the treatment of advanced solid tumors expressing urokinase plasminogen activator receptor; and MNPR-101-Zr, a clinical-stage radiodiagnostic imaging agent comprised of MNPR-101 conjugated to zirconium-89. It develops MNPR-101-Lu, a late-preclinical stage radiotherapeutic comprised of MNPR-101 conjugated to actinium-225. The company has collaborations NorthStar to develop radio-immuno-therapeutics targeting severe COVID-19. The company was founded in 2014 and is headquartered in Wilmette, Illinois.

MNPR Key Statistics

Market Cap

$467.78M

P/B Ratio

3.30

EPS

$-3.96

Employees

How MNPR Compares to Peers

MNPR is the smallest among peers, which may offer higher growth potential

P/E Rank

N/A

of 5

Margin Rank

N/A

of 5

Growth Rank

N/A

of 5

Size Rank

of 6

Company	Market Cap	P/E	Growth	Margin	Compare
MNPR(This stock)	$467.78M	N/A	0%	0.0%	-
AMGNAmgen Inc	$177.92B	25.6	0%	0.2%	vs AMGN
GILDGilead Sciences	$154.99B	19.3	0%	0.3%	vs GILD
VRTXVertex Pharmaceuticals	$113.16B	31.1	0%	0.3%	vs VRTX
REGNRegeneron Pharmaceuticals	$77.69B	17.6	0%	0.3%	vs REGN
BIIBBiogen Inc	$24.12B	15.0	0%	0.2%	vs BIIB

Monopar Therapeutics Company Information

Headquarters: Illinois; U.S.A
Website: www.monopartx.com
Sector: Health Care
Industry: Biotechnology

MNPR - Monopar Therapeutics

About Monopar Therapeutics

MNPR Key Statistics

How MNPR Compares to Peers

Monopar Therapeutics Company Information

MNPR Lician Score

MNPR Financial Snowflake

Upcoming Events for MNPR